epitinib   Click here for help

GtoPdb Ligand ID: 11608

Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
Compound class: Synthetic organic
Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 82.62
Molecular weight 430.21
XLogP 2.54
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCN1CCN(CC1)C(=O)Nc1cc2c(ncnc2cc1OC)Nc1cccc(c1)C#C
Isomeric SMILES CCN1CCN(CC1)C(=O)Nc1cc2c(ncnc2cc1OC)Nc1cccc(c1)C#C
InChI InChI=1S/C24H26N6O2/c1-4-17-7-6-8-18(13-17)27-23-19-14-21(22(32-3)15-20(19)25-16-26-23)28-24(31)30-11-9-29(5-2)10-12-30/h1,6-8,13-16H,5,9-12H2,2-3H3,(H,28,31)(H,25,26,27)
InChI Key DQAZPZIYEOGZAF-UHFFFAOYSA-N
References
1. Zhang W, Su W-G, Yang H, Cui Y, Ren Y, Yan X. (2010)
Quinazoline derivatives.
Patent number: WO2010002845A2. Assignee: Hutchison Medipharma. Priority date: 30/06/2008. Publication date: 13/07/2021.